626 related articles for article (PubMed ID: 29675844)
21. Modern drug delivery systems for targeting the posterior segment of the eye.
Peptu CA; Popa M; Savin C; Popa RF; Ochiuz L
Curr Pharm Des; 2015; 21(42):6055-69. PubMed ID: 26503152
[TBL] [Abstract][Full Text] [Related]
22. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
[TBL] [Abstract][Full Text] [Related]
23. Advances in ocular drug delivery.
Rawas-Qalaji M; Williams CA
Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
[TBL] [Abstract][Full Text] [Related]
24. Patent perspectives for corticosteroids based ophthalmic therapeutics.
Suresh PK; Sah AK
Recent Pat Drug Deliv Formul; 2014; 8(3):206-23. PubMed ID: 25020063
[TBL] [Abstract][Full Text] [Related]
25. Nanomaterials for ocular drug delivery.
Liu S; Jones L; Gu FX
Macromol Biosci; 2012 May; 12(5):608-20. PubMed ID: 22508445
[TBL] [Abstract][Full Text] [Related]
26. Nanotherapies for the treatment of ocular diseases.
Reimondez-Troitiño S; Csaba N; Alonso MJ; de la Fuente M
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):279-93. PubMed ID: 25725262
[TBL] [Abstract][Full Text] [Related]
27. Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins.
Radhakrishnan K; Sonali N; Moreno M; Nirmal J; Fernandez AA; Venkatraman S; Agrawal R
Drug Discov Today; 2017 Feb; 22(2):416-423. PubMed ID: 27818255
[TBL] [Abstract][Full Text] [Related]
28. Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.
Li H; Palamoor M; Jablonski MM
Nanotoxicology; 2016 Oct; 10(8):1152-9. PubMed ID: 27108911
[TBL] [Abstract][Full Text] [Related]
29. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
Fangueiro JF; Veiga F; Silva AM; Souto EB
Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
[TBL] [Abstract][Full Text] [Related]
30. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
Durgun ME; Güngör S; Özsoy Y
J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
[TBL] [Abstract][Full Text] [Related]
31. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.
Gote V; Ansong M; Pal D
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):885-906. PubMed ID: 32729364
[TBL] [Abstract][Full Text] [Related]
32. Nanotechnology in ocular delivery: current and future directions.
Sultana Y; Maurya DP; Iqbal Z; Aqil M
Drugs Today (Barc); 2011 Jun; 47(6):441-55. PubMed ID: 21695286
[TBL] [Abstract][Full Text] [Related]
33. Application of lipid nanoparticles to ocular drug delivery.
Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
[TBL] [Abstract][Full Text] [Related]
34. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
[TBL] [Abstract][Full Text] [Related]
35. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
Wang R; Gao Y; Liu A; Zhai G
J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
[TBL] [Abstract][Full Text] [Related]
36. Topical delivery of ocular therapeutics: carrier systems and physical methods.
Souza JG; Dias K; Pereira TA; Bernardi DS; Lopez RF
J Pharm Pharmacol; 2014 Apr; 66(4):507-30. PubMed ID: 24635555
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of the ocular therapeutic effect of prednisolone acetate by liposomal entrapment.
Elbialy NS; Abdol-Azim BM; Shafaa MW; El Shazly LH; El Shazly AH; Khalil WA
J Biomed Nanotechnol; 2013 Dec; 9(12):2105-16. PubMed ID: 24266264
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic implications of nanomedicine for ocular drug delivery.
Meng T; Kulkarni V; Simmers R; Brar V; Xu Q
Drug Discov Today; 2019 Aug; 24(8):1524-1538. PubMed ID: 31102733
[TBL] [Abstract][Full Text] [Related]
39. Ocular preparations: the formulation approach.
Kaur IP; Kanwar M
Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
[TBL] [Abstract][Full Text] [Related]
40. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
Babizhayev MA
Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
